September 11, 2020

Yorkshire company thrives despite COVID-19 challenges

It’s been another record-breaking year for EthOss Regeneration Ltd.

The firm, which produces ‘EthOss®’ – a ground-breaking synthetic biomaterial used during dental implant surgery, has also enjoyed growth in UK sales of 22 per cent and doubled the number of employees working in its head office.

This is all despite the firm losing three months of trading due to the Covid pandemic, which had a massive impact on the global dental industry.

Dr Paul Harrison, managing director of EthOss said: “We’re really pleased with our financial performance and company growth over the last year, despite the obvious challenges we have faced recently.

“In fact, due to our continued rapid growth, both in the UK and overseas, we will be moving into a new office and warehouse in Silsden imminently as we look to expand our operations further to cope with demand.

“Exports now account for 58 per cent of our total turnover and June 2020 was our best export month ever.

“Markets do appear to be recovering quickly and that record has already been surpassed in August, which has now become our biggest month of export sales to date.

“I am confident that we are weathering the Covid disruption and that our strategy not to put any staff on furlough and to use the period as an opportunity to invest in marketing and training and development is helping us to come back stronger than ever.

“We have a positive and successful future ahead as we look to continue to get a strong foothold in both our established and emerging markets across the globe. Our team’s dedication, commitment and enthusiasm has been instrumental in getting us to this point.”

View the “EthOss: A Year in Review” infographic

Dr Peter Fairbairn, lecturing at EthOss Congress in Manila, the Philippines, November 2019